Baicalin alleviates TNBS‑induced colitis by inhibiting PI3K/AKT pathway activation

  • Authors:
    • Lei Zhu
    • Hong Shen
    • Pei‑Qing Gu
    • Ya‑Jun Liu
    • Lu Zhang
    • Jia‑Fei Cheng
  • View Affiliations

  • Published online on: May 6, 2020     https://doi.org/10.3892/etm.2020.8718
  • Pages: 581-590
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Inflammatory bowel diseases (IBDs) are chronic immunological disorders of the intestinal tract characterized by persistent inflammation. Baicalin, a type of flavonoid, has exhibited a wide range of pharmacological activities, including immunomodulation and anti‑inflammation. However, little is known about the therapeutic role of baicalin in IBD. The aim of the present study was to ascertain whether baicalin could be a therapeutic drug of IBD and investigate its specific mechanisms. In the present study, the results revealed that baicalin not only significantly alleviated TNBS‑induced colitis by reducing the release of IL‑6, TNF‑α and IL‑1β and increasing the level of IL‑10, but promoted the expression of tight‑junction proteins ZO‑1 and β‑catenin, which may have been achieved by blockage of the PI3K/AKT signaling pathway. In vitro, the results demonstrated that baicalin clearly inhibited the release of TNF‑α, IL‑6 and IL‑1β and promoted the expression of IL‑10 in LPS‑induced HT‑29 cells, and significantly decreased LPS‑induced HT‑29 cell apoptosis by blockage of the PI3K/AKT signaling pathway. In conclusion, the present research revealed for the first time that baicalin acted as a therapeutic drug in IBD by suppression of the PI3K/AKT signaling pathway.

Related Articles

Journal Cover

July 2020
Volume 20 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Zhu, L., Shen, H., Gu, P., Liu, Y., Zhang, L., & Cheng, J. (2020). Baicalin alleviates TNBS‑induced colitis by inhibiting PI3K/AKT pathway activation. Experimental and Therapeutic Medicine, 20, 581-590. https://doi.org/10.3892/etm.2020.8718
MLA
Zhu, L., Shen, H., Gu, P., Liu, Y., Zhang, L., Cheng, J."Baicalin alleviates TNBS‑induced colitis by inhibiting PI3K/AKT pathway activation". Experimental and Therapeutic Medicine 20.1 (2020): 581-590.
Chicago
Zhu, L., Shen, H., Gu, P., Liu, Y., Zhang, L., Cheng, J."Baicalin alleviates TNBS‑induced colitis by inhibiting PI3K/AKT pathway activation". Experimental and Therapeutic Medicine 20, no. 1 (2020): 581-590. https://doi.org/10.3892/etm.2020.8718